Get access

Variation in Almotriptan Effectiveness According to Different Prophylactic Treatments

Authors

  • Pedro Emilio Bermejo MD,

    1. From Puerta de Hierro University Hospital – Neurology, Madrid, Spain (P.E. Bermejo); Hospital Sanitas la Zarzuela – Neurology, Madrid, Spain (R. Dorado); Sanatorio Del Rosario – Neurology, Madrid, Spain (J.M. Gomez-Arguelles).
    Search for more papers by this author
  • Rodolfo Dorado MD,

    1. From Puerta de Hierro University Hospital – Neurology, Madrid, Spain (P.E. Bermejo); Hospital Sanitas la Zarzuela – Neurology, Madrid, Spain (R. Dorado); Sanatorio Del Rosario – Neurology, Madrid, Spain (J.M. Gomez-Arguelles).
    Search for more papers by this author
  • Jose Maria Gomez-Arguelles PhD

    1. From Puerta de Hierro University Hospital – Neurology, Madrid, Spain (P.E. Bermejo); Hospital Sanitas la Zarzuela – Neurology, Madrid, Spain (R. Dorado); Sanatorio Del Rosario – Neurology, Madrid, Spain (J.M. Gomez-Arguelles).
    Search for more papers by this author

  • Conflict of Interest: None

P.EW. Bermejo, Puerta de Hierro University Hospital, Isla de Arosa, 37, 2B, Madrid, Spain 28035.

Abstract

Objective.— To evaluate the effect of different migraine prophylaxis medications on subject responsiveness to almotriptan.

Background.— There is evidence supporting an increase of responsiveness of symptomatic medications for migraine attacks by some prophylactic treatments although this has not been probed.

Methods.— A total of 345 patients (230 women, mean age 37.3) with episodic or chronic migraine were classified according to the prophylaxis they were taking in the following groups: (1) no prophylactic medication; (2) propranolol; (3) topiramate; (4) flunarizine. Decrease in Analogical Visual Scale and pain-free at 2 hours after almotriptan intake was assessed at 2 months. Side effects and discontinuation or treatment were also assessed.

Results.— Headache severity was reduced 4.2 in control group, 5.3 in propranolol group, 4.1 in topiramate group, and 4.0 in flunarizine group, whereas pain-free status was achieved in 37.3%, 48.7%, 36.1%, and 38.1% respectively. These two parameters were statistically significative between propranolol and control groups. Side effects were similar in all groups.

Conclusions.— Our results displayed a higher efficacy of almotriptan in propranolol group and we hypothesized it may be due to a common mechanism of action at serotoninergic receptors.

Get access to the full text of this article

Ancillary